DC_AC50
Based on 6 publication(s) in Google Scholar
DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). Inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance.
For research use only. We do not sell to patients.
- Purity: 99.98%
- CAS No.: 497061-48-0
- Formula: C17H12BrF2N3OS
- Molecular Weight:424.26
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) DC_AC50
More- Drug Resist Updat. 2023 Nov:71:101015. [Abstract]
- Cancer Lett. 2022 Jun 28;536:215651. [Abstract]
- Ecotoxicol Environ Saf. 2024 Jun 26:281:116641. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Dec 16;1872(3):168134. [Abstract]
- J Clin Transl Hepatol. 2025 Aug 28;13(8):630-643. [Abstract]
- BMC Pharmacol Toxicol. 2024 Aug 21;25(1):54. [Abstract]
Biological Activity
DC_AC50 exhibits IC50 values of 9.88 μM, 12.57 μM, 5.96 μM and 6.68 μM in Canine Abrams, Canine D1, human HOS and human MG63) cells, respectively[1].
DC_AC50 (0-10 μM)-treated cells are significantly less mitotically active, as demonstrated by decreased expression of phospho-histone H3 and cell cycle analysis[1].
DC_AC50 (10 μM) potentiates carboplatin-induced apoptosis in OSA cells and decreasesclonogenic survival[1].
DC_AC50 induces cell cycle arrest at both the 3 and 10 μM doses and DC_AC50 induces increase S phase cells dose-independently[1].
DC_AC50 (3 μM) inhibits the migration and of canine and human OSA cells[1].
DC_AC50 (2.5-10 μM) is highly efficient at inhibiting cancer cell proliferation (human lung cancer H1299 cells, leukaemia cancer K562 cells, breast cancer MDA-MB-231 cells and head and neck cancer 212LN cells) in a dose-dependent manner. DC_AC50 fails to exhibit any notable inhibition of the cell proliferation of human normal epithelial lung BEAS-2B cells or breast MCF-10A cells as control cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Canine OSA (Abrams, D1 and human OSA (HOS, MG63) cells.
-
Concentration:0-10 μM.
-
Incubation Time:72 h.
-
Result:Dose-dependently decreased viability of OSA cells.
-
Cell Line:Abrams and HOS cells.
-
Concentration:1, 3 and 10 μM (10 μM Carboplatin).
-
Incubation Time:24 h.
-
Result:Potentiated carboplatin-induced apoptosis.
Chemical Information
-
CAS No. 497061-48-0
-
Appearance Solid
-
Molecular Weight 424.26
-
Formula C17H12BrF2N3OS
-
Color White to off-white
-
SMILES
NC1=C(SC2=C1C=C3CCCC3=N2)C(NC4=C(Br)C=C(C=C4F)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Drug Resist Updat
CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress. [Abstract]2023 Nov:71:101015. PMID: 37924725 -
Cancer Lett
2022 Jun 28;536:215651. PMID: 35315340 -
Ecotoxicol Environ Saf
2024 Jun 26:281:116641. PMID: 38936053 -
Biochim Biophys Acta Mol Basis Dis
ATOX1-driven ECM degradation and vascular smooth muscle cell apoptosis accelerate aortic dissection progression. [Abstract]2025 Dec 16;1872(3):168134. PMID: 41412321 -
J Clin Transl Hepatol
ATOX1 Promotes Hepatocellular Carcinoma Carcinogenesis via Activation of the c-Myb/PI3K/AKT Signaling Pathway. [Abstract]2025 Aug 28;13(8):630-643. PMID: 40862287 -
BMC Pharmacol Toxicol
2024 Aug 21;25(1):54. PMID: 39169392
Solvent & Solubility
DMSO : 50 mg/mL (117.85 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jordon M Inkol, et al. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy. Vet Comp Oncol. 2020 Dec;18(4):559-569. [Content Brief]
[2]. Jing Wang, et al. Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. Nat Chem. 2015 Dec;7(12):968-79. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3570 mL | 11.7852 mL | 23.5705 mL | 58.9261 mL |
| 5 mM | 0.4714 mL | 2.3570 mL | 4.7141 mL | 11.7852 mL | |
| 10 mM | 0.2357 mL | 1.1785 mL | 2.3570 mL | 5.8926 mL | |
| 15 mM | 0.1571 mL | 0.7857 mL | 1.5714 mL | 3.9284 mL | |
| 20 mM | 0.1179 mL | 0.5893 mL | 1.1785 mL | 2.9463 mL | |
| 25 mM | 0.0943 mL | 0.4714 mL | 0.9428 mL | 2.3570 mL | |
| 30 mM | 0.0786 mL | 0.3928 mL | 0.7857 mL | 1.9642 mL | |
| 40 mM | 0.0589 mL | 0.2946 mL | 0.5893 mL | 1.4732 mL | |
| 50 mM | 0.0471 mL | 0.2357 mL | 0.4714 mL | 1.1785 mL | |
| 60 mM | 0.0393 mL | 0.1964 mL | 0.3928 mL | 0.9821 mL | |
| 80 mM | 0.0295 mL | 0.1473 mL | 0.2946 mL | 0.7366 mL | |
| 100 mM | 0.0236 mL | 0.1179 mL | 0.2357 mL | 0.5893 mL |
Powered by Bioz